Search

Your search keyword '"Foti, S."' showing total 681 results
Start Over Author "Foti, S."
681 results on '"Foti, S."'

5. A Simplified Methodology for the Assessment of the Seismic Risk Associated with Small Earth Dams

Author

Cosentini, R. M., Passeri, F., Foti, S., di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Calvetti, Francesco, editor, Cotecchia, Federica, editor, Galli, Andrea, editor, and Jommi, Cristina, editor

Published
2020
Full Text
View/download PDF

6. International benchmark on numerical simulations for 1D, nonlinear site response (Prenolin): Verification phase based on canonical cases

Author

Régnier, J, Bonilla, LF, Bard, PY, Bertrand, E, Hollender, F, Kawase, H, Sicilia, D, Arduino, P, Amorosi, A, Asimaki, D, Boldini, D, Chen, L, Chiaradonna, A, Demartin, F, Ebrille, M, Elgamal, A, Falcone, G, Foerster, E, Foti, S, Garini, E, Gazetas, G, Gélis, C, Ghofrani, A, Giannakou, A, Gingery, JR, Glinsky, N, Harmon, J, Hashash, Y, Iai, S, Jeremić, B, Kramer, S, Kontoe, S, Kristek, J, Lanzo, G, Di Lernia, A, Lopez-Caballero, F, Marot, M, McAllister, G, Mercerat, ED, Moczo, P, Montoya-Noguera, S, Musgrove, M, Nieto-Ferro, A, Pagliaroli, A, Pisanò, F, Richterova, A, Sajana, S, Santisi D’avila, MP, Shi, J, Silvestri, F, Taiebat, M, Tropeano, G, Verrucci, L, and Watanabe, K

Subjects
Geochemistry & Geophysics, Geophysics, Civil Engineering
Abstract

PREdiction of NOn-LINear soil behavior (PRENOLIN) is an international benchmark aiming to test multiple numerical simulation codes that are capable of predicting nonlinear seismic site response with various constitutive models. One of the objectives of this project is the assessment of the uncertainties associated with nonlinear simulation of 1D site effects. A first verification phase (i.e., comparison between numerical codes on simple idealistic cases) will be followed by a validation phase, comparing the predictions of such numerical estimations with actual strongmotion recordings obtained at well-known sites. The benchmark presently involves 21 teams and 23 different computational codes. We present here the main results of the verification phase dealing with simple cases. Three different idealized soil profiles were tested over a wide range of shear strains with different input motions and different boundary conditions at the sediment/bedrock interface. A first iteration focusing on the elastic and viscoelastic cases was proved to be useful to ensure a common understanding and to identify numerical issues before pursuing the nonlinear modeling. Besides minor mistakes in the implementation of input parameters and output units, the initial discrepancies between the numerical results can be attributed to (1) different understanding of the expression “input motion” in different communities, and (2) different implementations of material damping and possible numerical energy dissipation. The second round of computations thus allowed a convergence of all teams to the Haskell–Thomson analytical solution in elastic and viscoelastic cases. For nonlinear computations, we investigate the epistemic uncertainties related only to wave propagation modeling using different nonlinear constitutive models. Such epistemic uncertainties are shown to increase with the strain level and to reach values around 0.2 (log10 scale) for a peak ground acceleration of 5 m=s2 at the base of the soil column, which may be reduced by almost 50% when the various constitutive models used the same shear strength and damping implementation.

Published
2016

21. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project

Author

Trifiro, G., Isgro, V., Ingrasciotta, Y., Ientile, V., L'Abbate, L., Foti, S. S., Belleudi, V., Poggi, F., Fontana, A., Moretti, U., Lora, R., Sabaini, A., Senesi, I., Sorrentino, C., Puzo, M. R., Padula, A., Fusco, M., Giordana, R., Solfrini, V., Puccini, A., Rossi, P., Del Zotto, S., Leoni, O., Zanforlini, M., Ancona, D., Bavaro, V., Garau, D., Ledda, S., Scondotto, S., Allotta, A., Tuccori, M., Gini, R., Bucaneve, G., Franchini, D., Cavazzana, A., Biasi, V., Spila Alegiani, S., Massari, M., Andretta, I., Tanaglia, M., Carriero, A., Sassano, S., De Sarro, G., Mirarchi, S., Palleria, C., Sarro, C., Balestrieri, M., Rostan, S., Capuano, A., Bernardi, F. F., Trama, U., Russo, A., Fumo, M. G., Addis, A., Musicco, F., Sapigni, E., Mazzetti, I., Podetti, D., Potenza, A. M., Nikitina, V., Ricciardelli, R., Mogheiseh, N., Croce, S., Pettinelli, A., Ejlli, L., Fortino, I., Ercolanoni, M., Mazzone, A., Nisic, A., Schiatti, S., Ludergnani, M., Mancini, M., Patregnani, L., Fabbietti, P., Antonicelli, E., Mangano, A., Campomori, A., Urru, S. A., Costa, G., Guarrera, G. M., Stella, P., Serra, E., Carta, P., Vannacci, A., Lucenteforte, E., Parrilli, M., Convertino, I., De Giorgi, M., Rocchi, R. E., Rossi, M., Scroccaro, G., Deambrosis, P., Grindelli, G., Ferroni, E., Trifiro, G., Isgro, V., Ingrasciotta, Y., Ientile, V., L'Abbate, L., Foti, S. S., Belleudi, V., Poggi, F., Fontana, A., Moretti, U., Lora, R., Sabaini, A., Senesi, I., Sorrentino, C., Puzo, M. R., Padula, A., Fusco, M., Giordana, R., Solfrini, V., Puccini, A., Rossi, P., Del Zotto, S., Leoni, O., Zanforlini, M., Ancona, D., Bavaro, V., Garau, D., Ledda, S., Scondotto, S., Allotta, A., Tuccori, M., Gini, R., Bucaneve, G., Franchini, D., Cavazzana, A., Biasi, V., Spila Alegiani, S., Massari, M., Andretta, I., Tanaglia, M., Carriero, A., Sassano, S., De Sarro, G., Mirarchi, S., Palleria, C., Sarro, C., Balestrieri, M., Rostan, S., Capuano, A., Bernardi, F. F., Trama, U., Russo, A., Fumo, M. G., Addis, A., Musicco, F., Sapigni, E., Mazzetti, I., Podetti, D., Potenza, A. M., Nikitina, V., Ricciardelli, R., Mogheiseh, N., Croce, S., Pettinelli, A., Ejlli, L., Fortino, I., Ercolanoni, M., Mazzone, A., Nisic, A., Schiatti, S., Ludergnani, M., Mancini, M., Patregnani, L., Fabbietti, P., Antonicelli, E., Mangano, A., Campomori, A., Urru, S. A., Costa, G., Guarrera, G. M., Stella, P., Serra, E., Carta, P., Vannacci, A., Lucenteforte, E., Parrilli, M., Convertino, I., De Giorgi, M., Rocchi, R. E., Rossi, M., Scroccaro, G., Deambrosis, P., Grindelli, G., and Ferroni, E.

Subjects
Male, medicine.medical_specialty, Population, Postmarketing surveillance, Rate ratio, REGISTRIES, Retrospective Studie, Internal medicine, BIOSIMILARS, medicine, Adalimumab, Humans, Pharmacology (medical), Original Research Article, education, Adverse effect, ANTI-TNF THERAPY, RHEUMATOID-ARTHRITIS, RISK, PHARMACOVIGILANCE, BIOSIMILARS, EXPERIENCE, REGISTRIES, PSORIASIS, MEDICINES, ACCESS, Biosimilar Pharmaceuticals, Retrospective Studies, RISK, Delivery of Health Care, Female, Infliximab, Italy, SARS-CoV-2, COVID-19, Pharmacology, education.field_of_study, PSORIASIS, business.industry, Biosimilar, ANTI-TNF THERAPY, General Medicine, medicine.disease, RHEUMATOID-ARTHRITIS, PHARMACOVIGILANCE, MEDICINES, EXPERIENCE, Immune-mediated inflammatory diseases, ACCESS, business, Human, Biosimilar Pharmaceutical, Biotechnology, medicine.drug
Abstract

Background Biological drugs have improved the management of immune-mediated inflammatory diseases (IMIDs) despite being associated with important safety issues such as immunogenicity, infections, and malignancies in real-world settings. Objective The aim of this study was to explore the potential of a large Italian multi-database distributed network for use in the postmarketing surveillance of biological drugs, including biosimilars, in patients with IMID. Methods A retrospective cohort study was conducted using 13 Italian regional claims databases during 2010–2019. A tailor-made R-based tool developed for distributed analysis of claims data using a study-specific common data model was customized for this study. We measured the yearly prevalence of biological drug users and the frequency of switches between originator and biosimilars for infliximab, etanercept, and adalimumab separately and stratified them by calendar year and region. We then calculated the cumulative number of users and person-years (PYs) of exposure to individual biological drugs approved for IMIDs. For a number of safety outcomes (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-COV-2] infection), we conducted a sample power calculation to estimate the PYs of exposure required to investigate their association with individual biological drugs approved for IMIDs, considering different strengths of association. Results From a total underlying population of almost 50 million inhabitants from 13 Italian regions, we identified 143,602 (0.3%) biological drug users, with a cumulative exposure of 507,745 PYs during the entire follow-up. The mean age ± standard deviation of biological drug users was 49.3 ± 16.3, with a female-to-male ratio of 1.2. The age-adjusted yearly prevalence of biological drug users increased threefold from 0.7 per 1000 in 2010 to 2.1 per 1000 in 2019. Overall, we identified 40,996 users of biosimilars of tumor necrosis factor (TNF)-α inhibitors (i.e., etanercept, adalimumab, and infliximab) in the years 2015–2019. Of these, 46% (N = 18,845) switched at any time between originator and biosimilars or vice versa. To investigate a moderate association (incidence rate ratio 2) between biological drugs approved for IMIDs and safety events of interest, such as optic neuritis (lowest background incidence rate 10.4/100,000 PYs) or severe infection (highest background incidence rate 4312/100,000 PYs), a total of 43,311 PYs and 104 PYs of exposure to individual biological drugs, respectively, would be required. As such, using this network, of 15 individual biological drugs approved for IMIDs, the association with those adverse events could be investigated for four (27%) and 14 (93%), respectively. Conclusion The VALORE project multi-database network has access to data on more than 140,000 biological drug users (and > 0.5 million PYs) from 13 Italian regions during the years 2010–2019, which will be further expanded with the inclusion of data from other regions and more recent calendar years. Overall, the cumulated amount of person-time of exposure to biological drugs approved for IMIDs provides enough statistical power to investigate weak/moderate associations of almost all individual compounds and the most relevant safety outcomes. Moreover, this network may offer the opportunity to investigate the interchangeability of originator and biosimilars of several TNFα inhibitors in different therapeutic areas in real-world settings. Supplementary Information The online version contains supplementary material available at 10.1007/s40259-021-00498-3.

Published
2021

26. 1624P Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study

Author

Buffoni, M., Dalla Volta, A., Valcamonico, F., Apollo, D.D., Zivi, A., Procopio, G., Sepe, P., Del Conte, G., Di Meo, N., Foti, S., Zamboni, S., Messina, C., Lucchini, E., Rizzi, A., Ravanelli, M., Zamparini, M., Zacchi, F., Suardi, N., Farina, D., and Berruti, A.

Published
2024
Full Text
View/download PDF

40. Abiraterone versus Docetaxel in der Erstlinientherapie des metastasierten hormonsensitiven Prostatakarzinoms – ein multizentrischer Vergleich

Author

Dotzauer, R, Heidegger, I, Bektic, J, Kafka, M, Van den Bergh, R, Hunting, J, Thomas, A, Brandt, M, Höfner, T, Debedde, E, Thibault, C, Ermacora, P, Zattoni, F, Foti, S, Kretschmer, A, Ploussard, G, Rodler, S, von Amsberg, G, Tilki, D, Gandaglia, G, and Tsaur, I

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Docetaxel (D) oder eine sekundäre Hormonmanipulation (SHT) kombiniert mit einer Androgendeprivationstherapie (ADT) sind mögliche Behandlungsoptionen bei Patienten mit metastasiertem hormonsensitiven Prostatakarzinom (mHSPC). In Anbetracht der mangelnden Real-World-Evidenz war[zum vollständigen Text gelangen Sie über die oben angegebene URL], 61. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Published
2021
Full Text
View/download PDF

41. Docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer: a real-life analysis

Author

Tsaur, I., primary, Heidegger, I., additional, Bektic, J., additional, Kafka, M., additional, Van Den Bergh, R.C.N., additional, Hunting, J.C.B., additional, Thomas, A., additional, Brandt, M.P., additional, Höfner, T., additional, Debedde, E., additional, Thibault, C., additional, Ermacora, P., additional, Zattoni, F., additional, Foti, S., additional, Kretschmer, A., additional, Rodler, S., additional, Ploussard, G., additional, Von Amsberg, G., additional, Tilki, D., additional, Surcel, C., additional, Rosenzweig, B., additional, Gadot, M., additional, Gandaglia, G., additional, and Dotzauer, R., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results